Itraconazole

A triazole antifungal agent for fungal infections via inhibition of lanosterol 14α-demethylase; also has been shown to inhibit both the hedgehog signaling pathway and angiogenesis.Fungal Infection Approved (In Vitro) :Itraconazole has anti-proliferation of HUVEC (IC50 of 0.16 μM) .Itraconazole inhibits endothelial cell cycle progression at the G1 phase in vitro. (In Vivo) :Itraconazole (75-100 mg/kg; oral gavage; twice per day; for 18 days; female outbred athymic nude mice) treatment suppresses Hh pathway activity and the growth of medulloblastoma in a mouse allograft model.

Product Specifications

CAS Number

84625-61-6

Product Name Alternative

R51211

Field of Research

Pharmacology & Drug Discovery

Purity

>98% (HPLC)

Solubility

DMSO: ≥ 7.3 mg/mL

Smiles

O=C1N (C (CC) C) N=CN1C2=CC=C (N3CCN (C4=CC=C (OC[C@@H]5O[C@@] (CN6N=CN=C6) (C7=CC=C (Cl) C=C7Cl) OC5) C=C4) CC3) C=C2

Molecular Formula

C35H38Cl2N8O4

Molecular Weight

705.6334

Storage Conditions

Storage temperature: -20°C. Stability: ≥ 2 years

Notes

For research use only.

Other Product Names

3H-1,2,4-Triazol-3-one, 4-[4-[4-[4-[[ (2R,4S) -2- (2,4-dichlorophenyl) -2- (1H-1,2,4-triazol-1-ylmethyl) -1,3-dioxolan-4-yl]methoxy]phenyl]-1-piperazinyl]phenyl]-2,4-dihydro-2- (1-methylpropyl) -, rel-